CN-AML was significantly found in AML patients aged ≥ 40 years, and mutation of NPM1 and CEBPA genes were significantly exhibited in this group, therefore these driven gene mutations were associated with myeloid leukemia development in the middle aged and the older patients. The gene discussed is NPM1; the disease is myeloid leukemia.